Semaglutide May Cut Cardiovascular Risk Before Weight Loss

MÁLAGA, Spain — Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose — according to new data from the SELECT trial.
'The cumulative incidence of MACEs during the first 6 months showed a hazard ratio of 0.59,' said Donna Ryan, MD, professor emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana.
Ryan, a member of the SELECT steering committee, presented the data alongside Jorge Plutzky, MD, director of Preventive Cardiology at Brigham and Women's Hospital and professor of medicine at Harvard Medical School, Boston. The findings were presented at the European Congress on Obesity (ECO) 2025.
Early Benefits
The early cardiovascular (CV) benefit emerged before participants reached the target dose of semaglutide or experienced meaningful weight reduction.
The hazard ratio (HR) of MACEs for patients receiving semaglutide was 0.63 (95% CI, 0.41-0.95) during the first 3 months.
'The HRs for MACEs were below 1 before the weight loss started and before participants reached the top dose,' Ryan said. 'Almost immediately, the risk is less on semaglutide than on placebo.'
The first statistically significant reduction in MACEs occurred by day 20 after randomization, with sustained significance evident by day 86.
In the first 6 months, 67 MACEs occurred in the semaglutide arm vs 113 in the placebo arm (HR, 0.59; 95% CI, 0.44-0.80). The researchers observed a 53% reduction in CV deaths (14 deaths with semaglutide vs 30 deaths with placebo) and a 43% reduction in nonfatal myocardial infarction. The reduction in nonfatal stroke was not statistically significant (HR, 0.87; 95% CI, 0.47-1.58).
Design and Execution
These new findings add to results from the main SELECT trial, which previously was reported by Medscape Medical News . That trial found a 20% reduction in MACEs over nearly 40 months in patients with overweight or obesity and established CV disease (CVD; HR, 0.80; 95% CI, 0.72-0.90; P < .001).
'The design and precision of execution give us confidence in the results,' Ryan said.
SELECT enrolled 17,604 participants aged 45 years or older with overweight or obesity (body mass index ≥ 27) and established CVD, which was defined as prior myocardial infarction, stroke, or symptomatic peripheral artery disease. Eligible participants did not have type 2 diabetes, although two-thirds of participants had prediabetes. Participants were randomly assigned to once-weekly subcutaneous semaglutide or placebo (titrated to 2.4 mg by week 16) alongside standard-of-care treatments including statins, antihypertensives, and antiplatelet therapy.
'This was not a weight loss study,' Ryan emphasized. 'We thought that the drug itself might have properties beneficial to cardiovascular outcomes apart from weight loss.'
CV Benefits First
In the first 12 months, semaglutide was associated with a 9% reduction in body weight. However, this degree of weight loss was not yet apparent when the early CV benefit emerged.
At week 4, change in body weight was −1.1% for patients on semaglutide compared with placebos (95% CI, −1.2 to −1.1). By week 12, the difference was −3.6% (95% CI, −3.7 to −3.5).
To explore whether weight loss explained the early benefit, investigators compared daily hazard ratios for MACEs with average weight change over time. The dissociation between the curves suggested that the early CV benefit may occur independently of weight loss.
Potential Mechanisms
Asked to comment by Medscape Medical News , Jason Halford, PhD, head of the School of Psychology at the University of Leeds, Leeds, England, and past president of the European Association for the Study of Obesity, London, England, said that the results were surprising.
'This [study] suggests that [the benefits are] not mediated by weight loss and that there must be some other mechanism underpinning it,' Halford said. 'Possibly a reduction in inflammation, because obesity is an inflammatory disease, and it's a component of many other diseases.'
These findings may inform early treatment decisions in patients with obesity and CVD, even before significant weight loss has been achieved. Halford suggested that the findings could have implications for CV medicine. 'Of course, they are managing CVD with other therapies, and it would be interesting to compare not one antiobesity drug with another but to see how this impacts existing treatments for CVD. It might be preferable to use one drug to treat two things, for example.'
Halford also noted that as new antiobesity drugs and combinations of mechanisms emerge, comparisons should extend beyond weight loss to include CV outcomes. 'These early data shift the narrative. We knew the long-term benefits, but the short-term effect is unexpected.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Vogue

3 hours ago

• Vogue

I Drank Beet Juice Every Day for a Month—It Had This Unexpected Effect

Disclaimer: I am a caffeine fiend. I drink so much coffee that my local barista regularly chides me, reminding me 'it's not good for your heart' to start the day with a triple-shot flat white before 6 a.m. But when I became pregnant—and had to limit my daily caffeine intake to around 200 mg a day (or two single-shot coffees)—it was a struggle to say the least. Pre-pregnancy, I also indulged in nootropics, Diet Coke, and caffeine-infused anything to help me get through the day. But now? It was all a no. And I was flat out tired. That's when I stumbled upon a juice called the 'Fatigue Fighter' made of beets, apples, oranges, celery, and ginger. I was willing to give basically anything a try, and quickly downed an entire container. Delicious. But it wasn't until my energy soared that I became a believer. Read on for all the reasons that maybe you should give it a try, too. What are the benefits of drinking beet juice? I've waxed lyrical about my personal experience with beet juice, but what are the actual health benefits? Evelina Sabonaityte, MD and clinical nutritionist, claims that beet juice is 'a nutrient-packed elixir.' Here are some of the benefits of beet juice, according to Evelina and Dr Katy Kasraie, one of the general practitioners at The London General Practice.

Yahoo

4 hours ago

• Yahoo

The European Space Agency and Dassault Aviation paving the way for potential collaborations

PRESS RELEASE June 20, 2025 The European Space Agency and Dassault Aviation paving the way for potential collaborationsThe European Space Agency (ESA) has signed a Letter of Intent (LoI) with Dassault Aviation, a French civilian and military aircraft manufacturer recognized worldwide for its excellence, underlying their common interest to develop a closer relationship. ESA, with its ambitious strategy for space exploration, Explore2040, is seeking innovative solutions for capabilities development to reach and return from Low Earth Orbit (LEO), Moon and Mars, and supports the advancement of selected critical enabling technologies to be used and demonstrated in particular in LEO, such as hypervelocity re-entry. Dassault Aviation, also a leader in aerospace engineering, is developing its space activities with a focus on the design of a reusable spaceplane based on lifting bodies shapes that bridge aeronautical and space technologies. Their interest in automated LEO platforms suitable for commercial and institutional markets, led them to develop a vehicle concept called 'Véhicule Orbital Réutilisable de Transport et d'Exploration (VORTEX)', designed for research in space, transport of cargo to and from space stations, and a range of in-orbit services. This project is based on a considerable expertise in spaceplanes having participated in numerous programmes like Hermes, NASA X-38 Crew Rescue vehicle, ESA Intermediate eXperimental Vehicle (IXV) demonstrator, and Airborne Reusable Hypersonic Experimental Vehicle (VEHRA) concepts. 'Dassault Aviation's decades of expertise in aeronautical and space systems, perfectly position them to pioneer critical space technologies', said Josef Aschbacher, Director General of the European Space Agency. 'With VORTEX, Dassault is contributing to strengthening European capacities and securing sovereign access to space in a strongly growing and competitive space sector. We look forward to combining our expertise and working hand-in-hand for a stronger Europe in space.' 'Our Vortex roadmap aims to strengthen Europe's essential sovereign capabilities and meet the new challenges of the space economy. This letter of intent is a perfect recognition of the complementary expertise of the European Space Agency and Dassault Aviation in the development of critical technologies and innovative space solutions,' declared Eric Trappier, Chaiman and CEO of Dassault Aviation. As such, the signatories of the LoI, have identified a mutual interest in developing a closer relationship with the potential to commonly derisking critical technologies as well as to further explore the potential for collaboration in areas such as LEO destinations and particularly around orbital vehicules. As such, both foresee an interest to cooperate on a scaled down suborbital version of VORTEX, serving as a testbed, with a focus on, but not limited to: Designing, testing and qualifying key technologies and components. New materials and integration processes. Assessing the feasibility to include future payloads in case of the integration of a dedicated bay on the end-product. This joint work will be based on exchanging relevant information and conducting studies or preparatory activities, to help establish respective roles and responsibilities in the realisation of potential joint activities, leveraging on each side's capabilities. 'Europe benefits from a wide range of diverse and complementary skills. Enlarging the European industrial base is key for new opportunities arising in Space Exploration, aiming at more autonomy,' said Daniel Neuenschwander, Director of Human and Robotic Exploration at ESA. About the European Space Agency The European Space Agency (ESA) provides Europe's gateway to is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe's space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. ESA has 23 Member States: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Latvia, Lithuania and Slovakia are Associate Members. ESA has established formal cooperation with other four Member States of the EU. Canada takes part in some ESA programmes under a Cooperation Agreement. By coordinating the financial and intellectual resources of its members, ESA can undertake programmes and activities far beyond the scope of any single European country. It is working in particular with the EU on advancing the Galileo and Copernicus programmes as well as with Eumetsat for the development of meteorological missions. Learn more about ESA at Media contact: media@ About Dassault Aviation With over 10,000 military and civil aircraft delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized worldwide in the design, production, sale and support of all types of aircraft, ranging from the Rafale fighter, to the high-end Falcon family of business jets, military drones and space systems. In 2024, sales amounted to € 6.2 billion. Dassault Aviation has 14,600 employees. Dassault Aviation – PRESS CONTACTS Corporate Communications Stéphane Fort: +33 (0)1 47 11 86 90 - Mathieu Durand: +33 (0)1 47 11 85 88 - Export CommunicationsNathalie Bakhos Tel: +33 (0)1 47 11 84 12 Attachment PR_ESA Dassault VF 1Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data